In this study we sequenced 1345 BC/OC cases from 3 different Central- and East European countries with multi-gene panels and identified recurrent founder mutations in ERCC2, which were functionally validated in cell-culture based assays. The gene discussed is ERCC2; the disease is breast cancer.